The estimated Net Worth of Bruce Rogers is at least 13.5 百万$ dollars as of 8 July 2024. Bruce Rogers owns over 20,000 units of Morphic Inc stock worth over 9,681,632$ and over the last 5 years he sold MORF stock worth over 3,301,614$. In addition, he makes 528,711$ as Chief Scientific Officer at Morphic Inc.
Sign up
Bruce Rogers MORF stock SEC Form 4 insiders trading
Bruce has made over 18 trades of the Morphic Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of MORF stock worth 86,400$ on 8 July 2024.
The largest trade he's ever made was exercising 40,000 units of Morphic Inc stock on 9 September 2021 worth over 172,800$. On average, Bruce trades about 12,349 units every 63 days since 2020. As of 8 July 2024 he still owns at least 169,883 units of Morphic Inc stock.
You can see the complete history of Bruce Rogers stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Bruce Rogers biography
Dr. Bruce N. Rogers Ph.D. serves as Chief Scientific Officer of the Company. From June 2014 to January 2016, Dr. Rogers served as the Head of Neuro-Opportunities at Pfizer Inc. Prior to that position, Dr. Rogers held positions of increasing responsibility within the medicinal chemistry organization at Pfizer Global R&D since August 2003. Dr. Rogers started his career in the private sector at Pharmacia & Upjohn Company LLC as a scientist from September 1998 to August 2003. Dr. Rogers received a B.A. in Chemistry from the University of Minnesota, a Ph.D. in Organic Chemistry from the University of California at Irvine and was a National Institutes of Health postdoctoral fellow at the University of California.
What is the salary of Bruce Rogers?
As the Chief Scientific Officer of Morphic Inc, the total compensation of Bruce Rogers at Morphic Inc is 528,711$. There are 6 executives at Morphic Inc getting paid more, with Timothy Springer having the highest compensation of 1,260,500$.
How old is Bruce Rogers?
Bruce Rogers is 51, he's been the Chief Scientific Officer of Morphic Inc since 2016. There are 9 older and 8 younger executives at Morphic Inc. The oldest executive at Morphic Holding Inc is Dr. Timothy A. Springer Ph.D., 73, who is the Founder, Independent Director & Member of Scientific Advisory Board.
What's Bruce Rogers's mailing address?
Bruce's mailing address filed with the SEC is C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2, WALTHAM, MA, 02451.
Insiders trading at Morphic Inc
Over the last 5 years, insiders at Morphic Inc have traded over 69,316,197$ worth of Morphic Inc stock and bought 3,360,997 units worth 101,882,696$ . The most active insiders traders include Plc Gsk、Holdings A/S Novo、Timothy A Springer. On average, Morphic Inc executives and independent directors trade stock every 13 days with the average trade being worth of 2,254,353$. The most recent stock trade was executed by Bruce Rogers on 8 July 2024, trading 20,000 units of MORF stock currently worth 86,400$.
What does Morphic Inc do?
oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. morphic tx is joining a three decade quest led by our scientific founder, tim springer, who initially discovered the integrin receptor family in the 1980s. this receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.
What does Morphic Inc's logo look like?
Complete history of Bruce Rogers stock trades at Morphic Inc
Morphic Inc executives and stock owners
Morphic Inc executives and other stock owners filed with the SEC include:
-
Timothy Springer,
Founder, Independent Director -
Alexey Lugovskoy,
Chief Development Officer -
Dr. Praveen P. Tipirneni M.D.,
CEO, Pres & Director -
William DeVaul,
General Counsel, Secretary -
Praveen Tipirneni,
President, Chief Executive Officer, Director -
Dr. Marc Schegerin M.B.A., M.D.,
CFO & COO -
Bruce Rogers,
Chief Scientific Officer -
Vikas Goyal,
Independent Director -
Gustav Christensen,
Independent Chairman of the Board -
Joseph Slattery,
Independent Director -
Otello Stampacchia,
Independent Director -
Norbert Bischofberger,
Independent Director -
Amir Nashat,
Independent Director -
Dr. Timothy A. Springer Ph.D.,
Founder, Independent Director & Member of Scientific Advisory Board -
Nilesh Kumar,
Independent Director -
Peter Linde,
Chief Medical Officer -
Robert Farrell,
Senior Vice President - Finance, Chief Accounting Officer -
Marc Schegerin,
Chief Financial Officer, Chief Operating Officer -
Adrian S. Ray Ph.D.,
Sr. VP and Head of Biology & Translation -
Blaise Lippa,
Sr. VP of Molecular Discovery -
William D. DeVaul Esq.,
Gen. Counsel & Sec. -
Dr. Bruce N. Rogers,
Chief Scientific Officer -
Robert E. Farrell Jr., CPA, CPA,
Sr. VP of Fin./Operations & Chief Accounting Officer -
Susannah Gray,
-
Nisha Nanda,
-
Martin Edwards,
-
Holdings A/S Novo,
10% owner -
Plc Gsk,
Director -
Otello Stampacchia,
Director -
Fund V, L.P.Omega Fund V Gp...,
-
Simon Peter Cooper,
CMO